Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
Yun‐Fan Liaw, Rong‐Nan Chien, Chau‐Ting Yeh, Sun‐Lung Tsai, Chia‐Ming Chu – 30 December 2003 – Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication, but its long‐term use may be associated with HBV tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif mutation. To examine the clinical features and course after emergence of YMDD mutants, 55 patients who received lamivudine therapy over 104 weeks at our unit were assayed for YMDD mutation(s). Thirty‐two of them were found to have the YMDD mutation.